Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiploma Regulatory News (DPLM)

Share Price Information for Diploma (DPLM)

Share Price is delayed by 15 minutes
Get Live Data
7,130.00    80.00 (1.13%)
Bid:
7,110.00
Ask:
7,120.00
Spread: 10.00 (0.141%)
Market Cap: £9.56b
DPLM Live PriceLast checked at - London Stock Exchange

Intraday Diploma Share Chart

Acquisition

28 Aug 2007 07:02

Diploma PLC28 August 2007 12 CHARTERHOUSE SQUARE, LONDON EC1M 6AX TELEPHONE: +44 (0)20 7549 5700 FACSIMILE: +44 (0)20 7549 5715 FOR IMMEDIATE RELEASE 28 August 2007 DIPLOMA ACQUIRES 75% of AMT VANTAGE HOLDINGS INC. FOR A MAXIMUM OF £14.3m (C$30.0m) Diploma PLC, the international specialised distribution group, is pleased to announce the acquisition of 75% of AMT Vantage Holdings Inc. ("AMT"), a leading distributor of speciality electrosurgery and endoscopy equipment and related consumables to hospitals across Canada. AMT operates from a 10,000 square foot leasehold facility based in Kitchener, Ontario which is one hour south west of Toronto. The Company employs 32 staff. AMT supplies specialised equipment and consumables to physicians in hospitals when carrying out electrosurgical procedures. Products include surgical smoke evacuation; conductivity pads; electrodes; generators and probes and flexible endoscopic accessories. It has also established an operation to serve the new growth market for vessel sealing products. A large proportion (ca. 80%) of AMT's revenues comes from multi-year customer contracts with hospitals and buying groups. Sales efforts are focused on nurse managers, physicians and surgeons. AMT has strong long term relationships with its principal suppliers. AMT has delivered strong growth in recent years by penetrating the market with several specialised products. These are mostly consumable products and are typically supplied under multi-year contracts with hospitals, which gives a predictable base-load of business for the future. There is considerable scope for further organic growth with these products by increasing market penetration in existing and new customers. In addition, AMT is broadening its product offering by signing up new suppliers and leveraging its position in electro-surgery by expanding into other surgical disciplines and new markets. Prior to acquisition by Diploma PLC, AMT was owned equally by its management comprising Bruce MacDonald, Bill Roberts and Dan Webb. The minority interest of 25% in AMT will be retained by these three individuals. Put and Call options exist over the minority shares which can be exercised after three and five years, based on an agreed multiple of earnings and subject to a maximum cap. Bruce MacDonald and Bill Roberts will remain with AMT as directors and will work closely with the management of Somagen, a fellow group company. Somagen supplies clinical diagnostic products to hospital laboratories in Canada. AMT's sales in the year ended 30 November 2006 were C$17.9m (£8.6m). Its profit before tax was C$0.8m (£0.4m) after shareholder bonuses which will not apply after acquisition. Gross assets at 30 November 2006 were C$5.0m (£2.4m). The financial statements of AMT for the year ended 30 November 2006 were subject to a review engagement report in accordance with Canadian generally accepted standards for review engagements. A review engagement does not constitute an audit. At completion, net assets are expected to be approximately C$4.0m (£1.9m), including net cash of approximately C$1.0m (£0.5m). The initial cash consideration to be paid for 75% of the business, which will be met from the Group's existing cash resources, is C$27.5m (£13.1m), before acquisition costs. This may be subject to minor adjustment based on the net assets at completion. Further deferred consideration up to a maximum of C$2.5m (£1.2m) may be payable depending on the operating profit of AMT in the year ending 30 September 2008. The Board expects this acquisition to be earnings enhancing for the Group in the 2007/08 financial year. Bruce Thompson, Chief Executive of Diploma PLC said: "The acquisition of AMT fits with Diploma's strategy in its Life Sciences Canadian sector of increasing its presence in the health care market and will provide a solid impetus to further growth in this market." For further enquiries please contact: Bruce Thompson, Chief Executive Officer 020 7549 5700 Nigel Lingwood, Group Finance Director 020 7549 5705 Ian Seaton, Bankside Consultants 020 7367 8891 NOTE TO EDITORS: Diploma PLC is an international group of specialised distribution businessesoperating in three sectors: Life Sciences - suppliers of consumables, instrumentation and related servicesto research, environmental and clinical diagnostic laboratories. Principalcompanies are Anachem, a1-envirosciences and CBISS in Europe and Somagen inCanada. Seals - Suppliers of hydraulic seals, gaskets, cylinders and attachment kits forheavy mobile machinery. Principal companies are Hercules Bulldog SealingProducts and HKX in North America and FPE in the UK. Controls - Suppliers of specialised wiring, connectors, control devices andfasteners for a range of technically demanding applications. Principal companiesare IS Group in the UK and US, Sommer Filcon in Germany and Hawco in the UK. Within each of these sectors, the Diploma businesses serve industry segmentswith long term growth potential and with the opportunity for sustainablesuperior margins through the quality of customer service, depth of technicalsupport and value adding activities. Further information on Diploma PLC can be found at www.diplomaplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jun 20264:00 pmRNSAppointment of Non-Executive Director
21st May 20265:01 pmRNSDirector/PDMR Shareholding
19th May 20267:00 amRNSHalf Year Results
20th Apr 20265:33 pmRNSHolding(s) in Company
9th Apr 20261:16 pmRNSHolding(s) in Company
23rd Mar 20263:02 pmRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNSSignificant upgrade to FY26 guidance
27th Feb 20261:45 pmRNSAppointment of Non-Executive Director
27th Jan 20264:06 pmRNSHolding(s) in Company
16th Jan 20263:05 pmRNSDirector/PDMR Shareholding
15th Jan 202610:30 amRNSDirector/PDMR Shareholding
14th Jan 20263:53 pmRNSResult of AGM
14th Jan 20267:00 amRNSQ1 2026 Trading Update
22nd Dec 20257:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20251:33 pmRNSHolding(s) in Company
19th Dec 20251:33 pmRNSHolding(s) in Company
18th Dec 202510:52 amRNSHolding(s) in Company
17th Dec 20257:00 amRNSChief Financial Officer appointment
8th Dec 20257:00 amRNSAnnual Financial Report & Notice of AGM
1st Dec 20257:00 amRNSTotal Voting Rights
26th Nov 20257:00 amRNSDirector/PDMR Grant of LTIP Awards
19th Nov 20252:17 pmRNSDirector/PDMR Shareholding
19th Nov 20257:00 amRNSDirector/PDMR Shareholding
18th Nov 20257:00 amRNSPreliminary Results
13th Nov 20257:00 amRNSIssue of Shares & Total Voting Rights
7th Oct 20257:00 amRNSDirector Declaration
2nd Oct 20252:41 pmRNSHolding(s) in Company
14th Aug 20257:00 amRNSChief Financial Officer update
17th Jul 20257:00 amRNSQ3 Trading Update
2nd Jul 20259:49 amRNSHolding(s) in Company
20th Jun 20259:50 amRNSHolding(s) in Company
9th Jun 202512:50 pmRNSHolding(s) in Company
28th May 20259:27 amRNSHolding(s) in Company
21st May 20254:07 pmRNSDirector/PDMR Shareholding
20th May 20257:00 amRNSHalf-year Report
19th May 202511:02 amRNSHolding(s) in Company
19th May 202510:57 amRNSHolding(s) in Company
9th May 20254:24 pmRNSHolding(s) in Company
6th May 20259:32 amRNSHolding(s) in Company
11th Apr 20253:44 pmRNSHolding(s) in Company
3rd Apr 20257:03 amRNSDirector Declaration
25th Mar 20257:00 amRNSDirector/PDMR Shareholding
24th Mar 20259:36 amRNSHolding(s) in Company
24th Mar 20257:00 amRNSDirector/PDMR Shareholding
24th Mar 20257:00 amRNSDirector/PDMR Shareholding
18th Mar 20259:54 amRNSHolding(s) in Company
3rd Mar 202510:15 amRNSDirector Declaration - External Appointment
25th Feb 20257:00 amRNSHolding(s) in Company
14th Feb 20253:20 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.